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ABSTRACT
A strain of Klebsiella pneumoniae resistant to cefoxitin and oxyimino-cephalosporins, but susceptible to
cefepime, was isolated from an adult patient hospitalised in Taichung, Taiwan. Isoelectric focusing
revealed three b-lactamases with isoelectric points of 5.4, 8.2 and 7.9, respectively. Following PCR with
plasmid DNA templates and gene sequencing, these enzymes were shown to correspond to TEM-1,
SHV-5 and a novel DHA-1-like enzyme (designated DHA-3). The bla genes for TEM-1 and SHV-5 were
transferable, but the blaDHA-3 gene was non-self-transferable in conjugation experiments. All three bla
genes were successfully introduced by electrotransformation into an Escherichia coli recipient (DH5a),
resulting in a similar resistance profile to that observed in the original donor strain. Other K. pneumoniae
strains producing DHA-1-like enzymes have been identified previously in Taiwan, and this report
suggests that DHA-type b-lactamases are continuing to emerge in this country.
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INTRODUCTION
Plasmid-mediated AmpC b-lactamases (21 types)
have been detected in clinical isolates of Klebsiella
pneumoniae, Escherichia coli and Salmonella spp.
worldwide [1], including Taiwan. These enzymes
include CMY-2 in E. coli [2] and Salmonella Hadar
[3], and DHA-1 [4] and CMY-8 [5] in K. pneumo-
niae. Isolates of K. pneumoniae producing DHA-1
have disseminated within a university hospital in
southern Taiwan [4] and have also been identified
at a medical centre in northern Taiwan [6]. DHA-1
was the first inducible, plasmid-encoded AmpC
b-lactamase, and was created by mobilisation of
the blaDHA-1 gene with an upstream regulator
ampR gene from the Morganella morganii chromo-
some [7,8]. Similarly, DHA-2, a point-mutant
derivative of DHA-1, is an inducible, plasmid-
located cephalosporinase detected in an isolate of
K. pneumoniae from France [9]. The present study
describes the characterisation of a further novel
AmpC b-lactamase in a clinical isolate of
K. pneumoniae exhibiting resistance to cefoxitin,
cefotaxime and ceftazidime.
MATERIALS AND METHODS
Bacterial strains
K. pneumoniae strain KP3 was isolated in 2000 from an
aspirated, purulent specimen from an adult patient with a
liver abscess who was hospitalised at Veterans General
Hospital, Taichung, Taiwan. E. coli J53 (Azir) (sodium azide-
resistant) and E. coli DH5a were used as recipient strains in
conjugation and electroporation experiments, respectively.
Antimicrobial susceptibility testing
MICs were determined by the NCCLS macrodilution tube
method with Mueller–Hinton broth [10]. Quality control was
assured by testing E. coli ATCC 25922 and Pseudomonas
aeruginosa ATCC 27853. The antimicrobial agents investigated
included ampicillin, cephalothin, cefoxitin, cefotaxime (Sigma,
St Louis, MO, USA), ceftazidime (Glaxo, Greenford, UK),
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cefepime (Bristol-Myers Squibb, Princeton, NJ, USA), ciprofl-
oxacin (Bayer, Leverkusen, Germany) and imipenem (Merck
Sharp & Dohme, West Point, PA, USA). MICs of cefotaxime
and ceftazidime, with or without clavulanic acid (United States
Pharmacopoeia Convention Inc., Rockville, MD, USA) 4 mg ⁄L,
were compared as a test for the presence of extended-spectrum
b-lactamases (ESBLs) [10]. The ESBL phenotype was confirmed
by a reduction of ‡ 3 log2 dilutions in the MICs of either
cefotaxime or ceftazidime in the presence of clavulanic acid
[10].
Antagonism testing
The modified disk antagonism method [4] was used to detect
induction of chromosomal b-lactamases. Disks of inducing
agents anddisks of cephalosporinswereplacedon the surface of
Mueller–Hinton agar plates, 25 mm apart. The cephalosporin
disks (Becton Dickinson Microbiology Systems, Cockeysville,
MD, USA) were cefotaxime (30 lg), ceftazidime (30 lg), aztre-
onam (30 lg) and cefepime (30 lg). Clavulanic acid (10 lg) and
cefoxitin (30 lg) disks were used as inducing agents.
Analytical isoelectric focusing (IEF)
Crude protein extracts containing b-lactamases were prepared
by ultrasonication, followed by determination of isoelectric
points (pIs) by IEF on an ampholin polyacrylamide gel (pH 3.5–
9.5) [11]. Gels were developedwith 0.5 mMnitrocephin (Oxoid,
Basingstoke, UK). Standards of known pI included TEM-1
(pI 5.4), TEM-4 (pI 5.9), SHV-3 (pI 7.0), SHV-1 (pI 7.6), SHV-4
(pI 7.8) and SHV-5 (pI 8.2); pI values for unknown b-lactamases
were calculated by regression analysis.
Conjugation and electrotransformation experiments
Plasmid conjugation experiments were performed using E. coli
J53 (Azir) as the recipient [12]. Transconjugants were selected
on Luria–Bertani agar plates supplemented with sodium azide
(100 mg ⁄L) and cefotaxime (2 mg ⁄L). In addition, cefoxitin
(8 mg ⁄L) was added to prevent selection of ESBL-producing
transconjugants, and thus to separate an AmpC-encoding
plasmid if both ESBL- and AmpC-encoding plasmids were
present in the same donor strain. Electrotransformation of a
plasmid DNA suspension from K. pneumoniae KP3 into E. coli
DH5a was performed at a pulsed-field strength of 2.5 kV ⁄ cm
with a 15-lF capacitor and a 335-W resistor using an EasyjecT
Optima electroporator (Equibio, Nottingham, UK) as des-
cribed previously [13]. Electrotransformants were selected on
agar containing cefotaxime (2 mg ⁄L) or cefoxitin (8 mg ⁄L).
Plasmid DNA was extracted from K. pneumoniae KP3, E. coli
J53 transconjugants and E. coli DH5a electroporants with a
Plasmid Miniprep Purification Kit (Amersham Biosciences,
Uppsala, Sweden).
PCR-based amplification of b-lactamase genes and DNA
sequence analysis
TEM-, SHV- and AmpC-related genes (including those for
DHA-1, FOX-1 and CMY-2) were amplified using specific
primers as described previously [2,14–16]. PCR conditions
comprised 3 min at 94C, followed by 35 cycles of 1 min at
94C, 1 min at 55C and 2 min at 72C, with a final extension
period of 7 min at 72C. Amplicons were separated by
electrophoresis on agarose 1.5% w ⁄v gels and were visualised
by exposure to UV light in the presence of ethidium bromide.
DNA sequencing was performed on an automated DNA
sequencer (ABI PRISM 373; Applied Biosystems, Foster City,
CA, USA). Since the set of primers corresponding to the DHA-
1 gene gave a positive result, internal primers for putative
hybF, ampR and orf-1 sequences from the M. morganii chromo-
some were also used in an attempt to determine the genetic
context of the cephalosporinase gene [14]. To identify
DHA-related integrons, primers P1 (forward, 5¢-CGGAT-
GAAGGCAACCCA-3¢) and P2 (reverse, 5¢-AAGCAGACTTG-
ACCTGATAGT-3¢), specific for class 1 integrons, were used
in PCRs [17]. Furthermore, a specific pair of primers,
5¢-CTTTTGCCCTAGCTGCGGT-3¢ (forward) and 5¢-CTCAC-
GCCCTGGCAAGGTTT-3¢ (reverse), was used to amplify the
common region of In6–In7 at bp 3081–3675 [8].
Southern blot hybridisation
Plasmid DNA samples were analysed by electrophoresis at
30 V for 2 h on agarose 1% w ⁄v gels, denatured and then
neutralised on Whatman (Maidstone, UK) filter paper satur-
ated, successively, with sodium dodecyl sulphate 10% w ⁄v,
denaturation solution (0.5 M NaOH, 1.5 M NaCl) and neutral-
isation solution (0.5 M Tris-HCl, pH 7.5, 1.5 M NaCl) for
15 min each. Plasmid DNA was transferred to a positively
charged nylon membrane (Boehringer Mannheim, Mannheim,
Germany) using an electrophoretic transfer cell (Bio-Rad,
Hemel Hempstead, UK). A probe for DHA-1 was prepared
by random labelling of the 1140-bp blaDHA-1 PCR product with
digoxigenin (Digoxigenin Labelling and Detection Kit; Roche
Diagnostics, Mannheim, Germany) according to the manufac-
turer’s instructions.
RESULTS AND DISCUSSION
The strain of K. pneumoniae (KP3) with resistance
to cefoxitin and cefotaxime was isolated from a
liver abscess aspirate. It remained susceptible to
cefepime (0.5 mg ⁄L) and imipenem (0.25 mg ⁄L).
The high MICs of cefotaxime and ceftazidime
were not reduced by clavulanate (Table 1), sug-
gesting the presence of an AmpC-type enzyme
rather than an ESBL [10]. Induction of the
b-lactamases of KP3 was demonstrated by the
disk antagonism test, which demonstrated blunt-
ing of the zones surrounding the cephalosporin
disks adjacent to the inducers, including the
clavulanic acid and cefoxitin disks (Fig. 1).
IEF of crude extracts of KP3 and E. coli DH5a
(pKP3) transformants identified three b-lactamas-
es at pIs of 5.4, 7.9, and 8.2. In contrast, the E. coli
J53 (pKP3-1) transconjugant contained only two
b-lactamases with pIs of 5.4 and 8.2. The enzymes
with pIs of 5.4 and 8.2 were shown to correspond
to TEM-1 and SHV-5, respectively, by amplifica-
tion of the genes from the plasmid DNA of the
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clinical KP3 strain and the J53 (pKP3-1) trans-
conjugant, followed by DNA sequencing. The
naturally occurring SHV-1 enzyme (pI 7.6) of
K. pneumoniae was not identified on the IEF gel.
The ceftazidime MIC (32 mg ⁄L) for E. coli J53
(pKP3-1) was reduced significantly to 4 mg ⁄L in
the presence of clavulanic acid (Table 1), confirm-
ing the presence of an ESBL (SHV-5). However,
clavulanic acid did not reduce the MICs of ceftaz-
idime (128 mg ⁄mL) and cefotaxime (64 mg ⁄L) for
the original clinical isolate of K. pneumoniae (KP3)
(Table 1), suggesting that clavulanic acid itselfmay
act as an inducer of the non-transferred enzyme
(pI 7.9), rather than as an inhibitor of SHV-5, thus
leading to a false-negative result with the ESBL test
for KP3 (i.e., a net effect of no significant reduction
in the MICs of ceftazidime and cefotaxime).
Repeated conjugation experiments, regardless
of whether cefotaxime or cefoxitin was used as
the selecting agent, failed to demonstrate transfer
of a plasmid coding for the pI 7.9 b-lactamase.
However, this enzyme could be isolated from
E. coli DH5a (pKP3) electroporants and was
subsequently identified as a novel AmpC-like b-
lactamase (see below), termed ‘DHA-3’. Like the
plasmid carrying the blaDHA-1 gene, discovered in
strains of Salmonella enterica serovar Enteritidis
[7,8] and K. pneumoniae [4], the blaDHA-3 plasmid
was not self-transferable. The E. coli DH5a (pKP3)
electroporant had a similar resistance profile to
KP3 (Table 1).
Using a set of primers specific for blaDHA-1, a
1048-bp PCR fragment was obtained from plas-
mid DNA preparations of both KP3 and the E. coli
DH5a (pKP3) transformant. DNA sequencing of
both PCR products revealed a deduced protein
with only two amino-acid changes (DHA-3) com-
pared with DHA-1 (> 98% similarity; Fig. 2).
Repeated PCR and DNA sequencing gave the
same sequence for DHA-3, implying that the
mutation was not caused by random change.
Plasmid analysis by Southern hybridisation with
a blaDHA-1-specific probe showed that blaDHA was
localised on KP3 and DH5a (pKP3) plasmid
bands of > 10-kb (data not shown). However,
repeated electrotransformation experiments failed
to obtain an E. coli transformant carrying DHA-3
without SHV-5 and TEM-1. Therefore, precise
conclusions regarding the phenotypic effect of the
mutations that differentiated DHA-3 from DHA-1
were not possible.
Since DHA-1 and DHA-2 are known to be
inducible because of the presence of a reverse
transcribed ampRgene [7,9], primers targeted to the
3¢-ends of this ampR gene and the blaDHA-3 genes
allowed amplification from theplasmids carriedby
KP3 and E. coli DH5a (pKP3). Comparison of the
alignment of the deduced amino-acid sequence of
the DHA-3-associated AmpR with that of the
AmpR of M. morganii revealed 98% identity, with
only three amino-acid changes (Fig. 3). The 111-bp
inter-cistronic region of ampC and ampR contained
the promoter sequences for ampC and ampR
expression. This region was 100% identical to the
corresponding region of the Salmonella Enteritidis
plasmid that contained blaDHA-1 [7], and was 98%
identical to that found in the M. morganii chromo-
some [14]. Based on the inducible b-lactamase
activity of KP3 and the E. coli DH5a (KP3)
Fig. 1. Example of results obtained with double-disk
antagonism tests. ATM, aztreonam; CAZ, ceftazidime;
CTX, cefotaxime; FEP, cefepime; FOX, cefoxitin.
Table 1. MICs of various b-lactams for Klebsiella pneumo-
niae KP3, the Escherichia coli DH5a (pKP3) electroporant, E.
coli DH5a and the E. coli J53 (pKP3-1) transformant, as well
as pI values of the b-lactamases produced by each strain
Antimicrobial
agent
MIC (mg/L)
KP3
pI 5.4, 7.9, 8.2
DH5a DH5a (pKP3)
pI 5.4, 7.9, 8.2
J53(Azir) J53 (pKP3-1)
pI 5.4, 8.2
Ampicillin > 512 4 64 4 128
Cefoxitin 256 4 32 4 4
Cefotaxime 64 0.12 16 0.12 16
Cefotaxime–
clavulanatea
64 0.25 8 0.12 4
Ceftazidime 128 0.5 32 0.25 32
Ceftazidime–
clavulanatea
128 1 16 0.25 4
Cefepime 0.5 0.06 0.12 0.03 0.12
Ciprofloxacin 4 0.06 0.06 0.012 0.012
Imipenem 0.25 0.25 0.25 0.12 0.25
aClavulanate was tested at a fixed concentration of 4 mg ⁄L.
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transformant, as shown by the disk antagonism
test, the ampR gene should be functional, which
may make the DHA-3 enzyme inducible following
exposure to agents such as clavulanic acid. This
mayoffset the inhibitory effect of clavulanic acid on
the SHV-5 ESBL of KP3, resulting in uninhibited
Fig. 2. Alignment of deduced amino-acid sequences of DHA-3 from Klebsiella pneumoniae KP3 with those of DHA-1 from
Salmonella Enteritidis [7] and DHA-2 from K. pneumoniae 45956 [9]. Identical amino-acids are marked with dashes. The
underlined amino-acids are those that may be involved in the catalytic site of these AmpC enzymes, including the
b-lactamase active site S–V–S–K and the conserved triad K–T–G.
Fig. 3. Comparison of the alignment of the deduced amino-acid sequence of the AmpR protein of Klebsiella pneumoniae KP3
(Kp) with that of Morganella morganii (Mm) [14].
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MICsof ceftazidime and cefotaxime in thepresence
of clavulanic acid (Table 1).
The sequences surrounding blaDHA-3 were also
investigated using PCR to search for hybF and
orf-1. As observed for DHA-2 [9], hybF was
detected downstream of ampR, but orf-1 was not
identified on the plasmid from E. coli DH5a
(pKP3). These results were also indicative of the
M. morganii chromosomal origin of blaDHA-3.
Although ampR and blaDHA-1 were mobilised from
the M. morganii chromosome into a complex of
In6–In7–sulI-type class 1 integrons in a strain of
S. enterica serovar Enteritidis [8], a class 1 integron
carrying blaDHA-3 was not identified in KP3, nor
was an integron identified in the DHA-2-produ-
cing K. pneumoniae isolate described previously
[9]. Furthermore, PCRs using a pair of primers
specific to the common region of In6–In7 [8] did
not produce a positive reaction. However, the
possibility that point mutations in primer regions
have led to these negative results cannot be ruled
out.
In conclusion, the present study identified and
characterised the third plasmid-mediated cephalo-
sporinase derived from the chromosomally enco-
dedAmpCenzyme ofM.morganii. Identification of
the DHA-1 enzyme in klebsiellae in Taiwan [4,6],
together with the discovery of DHA-3 in the
present study, highlights the continued emergence
of DHA-related enzymes in K. pneumoniae in
clinical settings in Taiwan, where ESBL-producing
strains and other AmpC-producing Enterobacteri-
aceae have also become prevalent [2–6].
NUCLEOTIDE SEQUENCE
ACCESSION NUMBER
The nucleotide sequence reported in this paper
will appear under GenBank accession number
AY494945.
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